Direct isolation of circulating extracellular vesicles from blood for vascular risk profiling in type 2 diabetes mellitus

Tay, Hui Min; Leong, Sheng Yuan; Xu, Xiaohan; Kong, Fang; Upadya, Megha; Dalan, Rinkoo; Tay, Chor Yong; Dao, Ming; Suresh, S.; Hou, Han Wei

doi:10.1039/d1lc00333j

Cited by 37 publications

(42 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies shown that patients with T2DM led to impairment in endothelial-dependent vasodilatation, decreased expression of NO, showing a dysfunction of cardiovascular and endothelial. ( Néri et al, 2021 ; Tay et al, 2021 ; Wang et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota

Chen

Yang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Objective: To evaluate the protective effect of Polyethylene Glycol Loxenatide Injection (Glucagon-like peptide-1, GLP-1) on endothelial cells from middle-aged and elderly patients with newly diagnosed or poorly controlled type 2 diabetes mellitus (T2DM). GLP-1 weekly formulation was analyzed for cardiovascular disease protection and correlated with intestinal flora.Design: Stool samples were collected from middle-aged and elderly patients with new-onset or poorly controlled type 2 diabetes in Longhu People’s Hospital and Shantou Central Hospital from June 2019 to November 2019. Samples were collected at week 0, 4, and 8 of treatment with GLP-1 weekly formulations. Samples were analyzed for metagenomic sequencing. Analysis was performed to compare the characteristics of the gut microbiota at week 0, 4, and 8 of GLP-1 treatment and to correlate different microbiota with characteristic clinical parameters.Results: Statistical differences were found in blood glucose lowering, cardiovascular endothelial, and inflammation-related indices between week 0 and W4 and in blood glucose lowering and cardiovascular endothelial indices from week 0 to 8 in the newly diagnosed or poorly controlled type 2 diabetic patients treated with GLP-1. Changes in gut microbiota at week 0, 4, and 8 after using GLP-1 were not statistically different, but had an overall trend of rising and then falling, and with different bacteria, that were correlated with different clinical indicators.Conclusion: GLP-1 improves endothelial cell function indicators in middle-aged and elderly diabetic patients, which may be related to its alteration of the population numbers of gut microbiota such as Acinetobacter, Eubacterium ramulus ATCC 29099, and Bacteroides_faecis. This study provides a guidance for the treatment of type 2 diabetic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota

Chen

Yang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

Section: Emerging Separation Techniquementioning

confidence: 99%

“…This can simplify the fabrication process and operation difficulty of microfluidic devices. To illustrate, Tay and others have developed a novel inertial-based microfluidic device for directly separating exosomes and microvesicles from whole blood with 15% (±3.8%) separation efficiency within an hour ( Figure 6D ) ( Tay et al, 2021 ). Although the separation efficiency is limited, the method does not require functionalization with antibodies or external force field and performs directly separation of whole blood, hence providing a low device cost, portable, and promising strategy.…”

Section: Emerging Separation Techniquementioning

confidence: 99%

Review on Strategies and Technologies for Exosome Isolation and Purification

Chen

Zhang

et al. 2022

Front. Bioeng. Biotechnol.

274

166

View full text Add to dashboard Cite

Exosomes, a nano-sized subtype of extracellular vesicles secreted from almost all living cells, are capable of transferring cell-specific constituents of the source cell to the recipient cell. Cumulative evidence has revealed exosomes play an irreplaceable role in prognostic, diagnostic, and even therapeutic aspects. A method that can efficiently provide intact and pure exosomes samples is the first step to both exosome-based liquid biopsies and therapeutics. Unfortunately, common exosomal separation techniques suffer from operation complexity, time consumption, large sample volumes and low purity, posing significant challenges for exosomal downstream analysis. Efficient, simple, and affordable methods to isolate exosomes are crucial to carrying out relevant researches. In the last decade, emerging technologies, especially microfluidic chips, have proposed superior strategies for exosome isolation and exhibited fascinating performances. While many excellent reviews have overviewed various methods, a compressive review including updated/improved methods for exosomal isolation is indispensable. Herein, we first overview exosomal properties, biogenesis, contents, and functions. Then, we briefly outline the conventional technologies and discuss the challenges of clinical applications of these technologies. Finally, we review emerging exosomal isolation strategies and large-scale GMP production of engineered exosomes to open up future perspectives of next-generation Exo-devices for cancer diagnosis and treatment.

show abstract

“…In addition, microfluidic technology has also been applied in disease diagnosis, bacterial screening, immune biochemical reaction, enzyme protein recognition, organoid technology, and other fields. In 2021, the ExoDFF ( Tay et al, 2021 ) microfluidic chip developed by Hou et al from Nanyang Technological University was used to evaluate the vascular health of diabetes patients. ExoDFF uses centrifugal force and hydrodynamics to separate vesicle cells from blood for analysis.…”

Section: Some Recent Research On Microfluidic Chipsmentioning

confidence: 99%

“…Compared with a traditional blood separator, the cost of the ExoDFF chip is only a few yuan, and this greatly reduces the cost of detection. The chip is helps patients to monitor their vascular health instantly and quickly, and has a huge commercial potential ( Tay et al, 2021 ). In July 2021, Science reported that a microfluidic glass chip called high throughtput-microfluidic enzyme kinetics (HT-MEK) ( Reardon, 2021 ) can test for mutations in more than 1000 enzymes at once in just a few hours.…”

Section: Some Recent Research On Microfluidic Chipsmentioning

confidence: 99%

Microfluidic technology and its application in the point-of-care testing field

Xie

Dai

Yang

2022

Biosensors and Bioelectronics: X

View full text Add to dashboard Cite

Since the outbreak of the coronavirus disease 2019 (COVID-19), countries around the world have suffered heavy losses of life and property. The global pandemic poses a challenge to the global public health system, and public health organizations around the world are actively looking for ways to quickly and efficiently screen for viruses. Point-of-care testing (POCT), as a fast, portable, and instant detection method, is of great significance in infectious disease detection, disease screening, pre-disease prevention, postoperative treatment, and other fields. Microfluidic technology is a comprehensive technology that involves various interdisciplinary disciplines. It is also known as a lab-on-a-chip (LOC), and can concentrate biological and chemical experiments in traditional laboratories on a chip of several square centimeters with high integration. Therefore, microfluidic devices have become the primary implementation platform of POCT technology. POCT devices based on microfluidic technology combine the advantages of both POCT and microfluids, and are expected to shine in the biomedical field. This review introduces microfluidic technology and its applications in combination with other technologies.

show abstract

Direct isolation of circulating extracellular vesicles from blood for vascular risk profiling in type 2 diabetes mellitus

Abstract: Extracellular vesicles (EVs) are key mediators of communication among cells, and clinical utilities of EVs-based biomarkers remain limited due to difficulties in isolating EVs from whole blood reliably. We report...

Cited by 37 publications

References 65 publications

Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota

Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota

Review on Strategies and Technologies for Exosome Isolation and Purification

Microfluidic technology and its application in the point-of-care testing field

Contact Info

Product

Resources

About